Robert G. Maki

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

109h-index54.5kcitations747works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(429), Gastrointestinal Tumor Research and Treatment(127), Vascular Tumors and Angiosarcomas(124), Cardiac tumors and thrombi(89), Gastric Cancer Management and Outcomes(61)

Publications745 total

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Cancer Research Communications·2025Open Access
Efficacy of carotid artery stenting in patients with symptomatic low-grade carotid artery stenosis
Journal of neurosurgery·2025
Data from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
2025Open Access
Supplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
2025Open Access
From Headache to PRES: Early Recognition of Preeclampsia in a Pregnant Patient
Journal of Medical and Health Studies·2025Open Access
2743TiP First-in-human (FIH) phase I/II study of ADCE-D01, a urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload, in patients with metastatic and/or unresectable soft tissue sarcoma (STS)
Annals of Oncology·2025
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy
Journal for ImmunoTherapy of Cancer·2025Open Access
Author response: NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in solitary fibrous tumors
2025Open Access
NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in solitary fibrous tumors
eLife·2025Open Access
ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Clinical Cancer Research·2025
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma
JCO Precision Oncology·2025
Supplemental data for "Autonomous Agricultural Equipment Evaluation for Broad-Acre Crop Production"
2025Open Access
Supplemental data for "Autonomous Agricultural Equipment Evaluation for Broad-Acre Crop Production"
2025Open Access
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Long-term outcomes in GIST Trial 13-162: Phase II study of imatinib in combination with binimetinib in untreated patients with advanced gastrointestinal stromal tumor (GIST).
Journal of Clinical Oncology·2025
Early-Phase Trials in <i>Journal of Clinical Oncology</i>
Journal of Clinical Oncology·2025· 1 cited
Abstract CT196: Phase 1 dose escalation and expansion study of the PTK7-targeted antibody-drug conjugate DAY301 in patients with locally advanced or metastatic solid tumors
Cancer Research·2025
Assessment of the Mechanisms of Action of Eribulin in Patients with Advanced Liposarcoma Through the Evaluation of Radiological, Functional, and Tissue Responses: A Prospective Monocentric Study (Malibu Study)
Cancers·2025Open Access
NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in Solitary Fibrous Tumors
2025Open Access
Author response: NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in Solitary Fibrous Tumors
2025Open Access
page 1 of 38Next →

Frequent Co-authors

Cristina R. Antonescu(24), George D. Demetri(12), Samuel Singer(12), Ronald P. DeMatteo(11), Murray F. Brennan(8), Margaret von Mehren(7), Shreyaskumar Patel(7), Scott M. Schuetze(6), David R. D’Adamo(6), Jean‐Yves Blay(5), Peter Besmer(5), Gary K. Schwartz(5), Eunice L. Kwak(4), Keith D. Wilner(4), Jeffrey W. Clark(4), Peter Hohenberger(4), Steven Attia(4), Richard F. Riedel(4), Laurence H. Baker(4), Denise K. Reinke(4)